CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Zylox-Tonbridge, GL Capital Agree to Buy 16.7% Stake in LifeTech for HKD 1.48 Billion

By Public Technologies
  • Zylox-Tonbridge and GL Capital will invest approximately HKD 1.48 billion in newly issued LifeTech shares, securing a 16.7% stake through Lighthouse Two.
  • Lighthouse Two will become LifeTech’s largest single shareholder; Zylox-Tonbridge will invest approximately HKD 889 million for 60% of the investment vehicle.
  • GL Capital will subscribe for 39,800,000 newly issued Zylox-Tonbridge shares at HKD 22 each, representing approximately 10.8% of enlarged share capital.
  • The subscription price represents a 13.5% premium to the announcement-day closing price; proceeds will support potential LifeTech investments and international business development.
  • A potential merger with LifeTech is also planned to build an integrated vascular and structural heart intervention platform in China.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zylox-Tonbridge Medical Technology Co .Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611061240PR_NEWS_USPR_____CN91426) on November 06, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk